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Introduction
Upper limb tremor is a common movement disorder, with a range of  
etiologies and clinical presentations. The disorder often results in a marked 
impairment of  activities of  daily living (ADL).1 There are consensus guide-
lines on the first-line treatment of  the two main diseases that lead to upper 
limb tremor: essential tremor (ET)2,3 and Parkinson’s disease (PD)4. However, 
the management of  other causes of  tremor is less well defined. In ET, the 
question of  second-line treatment frequently arises in practice, and there 
are no guidelines on how many oral medications should be tried before 
considering botulinum neurotoxin (BoNT) injections or neurosurgery.
In fact, BoNT’s poorly defined role in the treatment of  upper limb 
tremor is mainly due to the lack of  data on its efficacy in general and the 
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Abstract
Background: Botulinum neurotoxin’s degree of  effectiveness on upper limb tremor is subject to debate; although this treatment reduces the tremor’s amplitude, 
a clear functional benefit has not been demonstrated. The objective of  this study was to assess the effect of  botulinum neurotoxin type A treatment on activities of  
daily living and quality of  life in patients with upper limb tremor.
Methods: We retrospectively examined the medical records of  50 consecutive patients treated with botulinum neurotoxin for upper limb tremor that was refrac-
tory to oral medication. One month after the injection, the patient was evaluated according to the Quality of  Life in Essential Tremor Questionnaire, and the 
Essential Tremor Embarrassment Assessment.
Results: Full data sets were available for 38 patients suffering variously from essential tremor (n = 21), Holmes tremor secondary to a focal brain lesion (n = 8), 
idiopathic dystonic tremor (n = 4), primary writing tremor (n = 4), and Parkinson's disease (n = 1). The Quality of  Life Essential Tremor Questionnaire and the 
Essential Tremor Embarrassment Assessment scores improved significantly (p < 0.001) in the study population as a whole, and in the essential tremor and Holmes 
tremor subgroups.
Discussion: Botulinum neurotoxin treatment of  patients with upper limb tremor is associated with improved quality of  life and activities of  daily living, irrespec-
tive of  the tremor’s etiology. Long-term treatment enables the physician to adjust the injection strategy to the patient’s needs. Our study was limited by its retrospec-
tive design. The results must therefore be confirmed in a prospective, double-blind, placebo-controlled, randomized clinical trial.
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impact on quality of  life (QoL) and ADL (i.e., functional benefit) in 
particular. The first double-blind trial in patients with ET showed that 
BoNT injections did not provide a functional improvement, even though 
the tremor amplitude was significantly lower.5–7 This limited benefit was 
explained by the occurrence of  side effects (reversible hand weakness) 
and by a slight improvement in kinetic tremor. Moreover, only a small 
number of  muscles were treated in these pioneering studies, and the 
BoNT dose levels were fixed. In an open-label study of  20 patients with 
ET, Pacchetti et al.8 reported an improvement on the Bain and Findley 
Activities of  Daily Living scale9 and a reduction in a tremor severity 
score10 1 month and then 3 months after the injection. The effect on 
QoL was not evaluated. Several recent studies have suggested that the 
choice of  the target muscles and the dose of  BoNT can be based on a 
kinematic analysis (i.e., a multisensor technique capable of  characteriz-
ing tremor at various joints)11–14 or a combined clinical/electrophysio-
logical approach.15 All of  these studies demonstrated a reduction in the 
tremor amplitude; however, the effect on functional abilities was either 
not assessed or gave conflicting results. Finally, Niemann and Jankovic16 
did not report on QoL and ADL in their retrospective evaluation of  a 
large cohort of  patients with hand tremor (due to various etiologies) 
receiving long-term BoNT-A treatment.
The use of  BoNT to treat upper limb tremor in patients with PD has 
been assessed in a few studies.12,17–19 A benefit was seen for tremor sever-
ity. However, the results for functional achievement (when assessed) were 
more debatable; for example, QoL did not change significantly.12 Even 
fewer studies have assessed etiologies of  upper limb tremor other than 
PD and ET. Vielotte et al.20 retrospectively explored the effect of  BoNT 
injections on cerebellar tremor. An improvement was noted, but it did 
not achieve statistical significance. In another retrospective study, Kim 
et al.21 assessed a group of  21 patients with proximal upper limb tremor 
(due to dystonia, in most cases). Of  the patients, 63% reported a func-
tional benefit, and 68% received long-term treatment.
The objective of  the present study of  a cohort of  patients with upper 
limb tremor (due to various etiologies) was to assess the effectiveness of  
repeated BoNT type A injections on ADL and QoL.
Methods
The study was performed in accordance with the ethical standards 
detailed in the Declaration of  Helsinki, and it was registered with the 
French National Data Protection Commission (Commission Nationale de 
l’Informatique et des Libertés; reference: DEC16-241). Written, informed 
consent was obtained from all the study participants.
We retrospectively examined the medical records of  consecutive 
patients treated with BoNT type A injections for upper limb tremor 
(due to various etiologies) in the Movement Disorders Department at 
Lille University Medical Center between January 2016 and June 2018. 
Each patient’s tremor was classified according to the most recent con-
sensus statement from the International Parkinson and Movement 
Disorders Society.22 The following data were collected with regard to 
QoL and ADL: the Quality of  Life for Essential Tremor (QUEST)23 
and the Essential Tremor Embarrassment Assessment (ETEA)24 on the 
day of  the last injection and 1 month after the last injection (via a phone 
call). The QUEST is a specific measure of  tremor-related QoL, with 
good acceptability; it was designed to assess ET but has also been used 
in PD.1 The ETEA explores tremor-related embarrassment in various 
ADL and takes account of  both motor disability and psychosocial fea-
tures. We also noted basic demographic characteristics (gender and 
date of  birth). To characterize the tremor, we noted the etiology, the age 
at onset, the affected body sites (fingers, hand, forearm and/or arm), 
the tremor mode (flexion-extension, pronosupination, abduction-ad-
duction, and internal-external rotation), and any previous medical 
treatments. With regard to the treatment, we recorded the patient’s age 
at the first BoNT injection and the last injection, total number of  cycles, 
muscles injected, drugs used, dose of  the first injection, dose of  the last 
injection, patient-rated Clinical Global Impression-Improvement 
(CGI-I) score,25 side effects (if  any) 1 month after the last injection (via 
a phone call), and the reason for discontinuing treatment (if  applicable). 
The BoNT dose was calculated in onabotulinumtoxin A units, since the 
latter drug was used for the great majority of  the injections. If  another 
toxin was injected, the following ratios were used: incobotulinumtoxin 
A:onabotulinumtoxin A 1:1 or abobotulinumtoxin A:onabotulinumtoxin 
A 3:1. The choice of  the target muscles was mainly based on a clinical 
examination, although Electromyography (EMG) was sometimes used 
to select one of  several muscles with similar actions (e.g., the pronator 
teres vs. the pronator quadratus). All the injections were performed 
using ultrasound guidance (Sonosite Edge, Sonosite Inc., Bothell, WA) 
by the same physician (AK).
Data analysis
Statistical analyses were performed using IBM SPSS Statistics for 
Windows software (version 22.0; IBM Corp., Armonk, NY), with the 
exception of  the Shapiro–Wilk test (using statistical tools for 
high-throughput data analysis; www.sthda.com/french/rsthda/ 
shapiro-wilk.php), the chi-squared test, and Fisher’s exact test (using 
the BiostaTGV website at biostatgv.sentiweb.fr). The threshold for sta-
tistical significance was set to p < 0.05. For quantitative variables, the 
Shapiro–Wilk test was used to study the normality of  the data distri-
bution, and intergroup comparisons were performed using Student’s 
t-test or the Mann–Whitney U test. For qualitative data, intergroup 
comparisons were performed using the chi-squared test or Fisher’s 
exact test (depending on the sample size). Correlations between data 
sets were assessed by calculation of  Pearson’s correlation coefficient. 
All quantitative data were quoted as the mean ± standard deviation 
(median; range).
Results
We assessed the medical records of  50 patients, whose demographic 
and clinical data are summarized in Table 1. The etiologies of  the 
tremor were as follows: ET (n = 24), Holmes tremor (HT) (n = 11, all 
due to a focal cerebral lesion), primary writing tremor (n = 5), idiopathic 
dystonic tremor (n = 5), intention tremor (IT) (n = 4, all due to a focal 
cerebellar lesion), and PD (n = 1). In patients with a focal cerebral 
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lesion, the tremor (HT or IT) had started within days to months (maxi-
mum: 1 year) of  the diagnosis. A family history of  tremor was noted in 
eight patients with ET (33.3%). The per os medications tried unsuccess-
fully prior to the BoNT injections are indicated in Supplementary 
Table 1. During the 30-month study period, 11 patients were lost to 
follow-up (injections not effective: n = 5; deceased: n = 3; side effects: 
n = 1; another disease: n = 1; unknown: n = 1), and one patient could 
not be contacted by phone.
The data presented below came from the 38 patients in whom the 
effects of  BoNT injections on ADL (according to the ETEA) and QoL 
(according to the QUEST) had been evaluated in a follow-up phone 
call. The 38 patients’ demographic and clinical data are also summa-
rized in Table 1. The characteristics of  the BoNT injections are summa-
rized in Table 2. Some comparisons between the two main subgroups of  
patients (ET and HT) are summarized in Table 3. The ETEA and 
QUEST scores before and after the BoNT injection, and the patient-
rated CGI-I score 1 month after the injections, are summarized in 
Table 4. At baseline, the ETEA score (but not the QUEST score) 
indicated that the tremor was less severe in the ET subgroup than in the 
HT subgroup (p = .045). The ETEA and QUEST scores 1 month after 
the injections evidenced a significant improvement in the group of  38 
patients and in the ET and HT subgroups. The patient-rated CGI-I 
score 1 month after the injections was 0 (i.e., not assessed) in 1 patient 
(2.6%), 1 (very much improved) in 10 patients (26.3%), 2 (much 
improved) in 15 patients (39.5%), 3 (minimally improved) in 9 patients 
(23.7%), and 4 (no change) in 3 patients (7.9%).
No correlation was found between tremor severity (according to the 
ETEA or QUEST score at the time of  the last injection) and age or 
disease duration (for all patients or for the ET and HT subgroups). 
Neither the CGI-I score, the improvement in the ETEA score, or the 
improvement in the QUEST score 1 month after the injection was cor-
related with age or disease duration. The CGI-I score 1 month after the 
injections was not correlated with the improvement in the ETEA or 
QUEST score. The improvements in the ETEA and QUEST scores 1 
month after the injections were correlated (Pearson’s correlation coeffi-
cient; r = 0.54; p < 10-6).
Table 1. Demographic and Clinical Data
Group/etiology Gender Age at onset* Main tremor modes
Thumb F-E Hand F-E Forearm F-E Forearm P-S Arm Ab-Ad Arm I-E rot
All patients treated 





5 37 16 37 20 10
Patients interviewed 



















1 5 4 5 4 4
Others (PWT = 4; 
IDT = 4; PD = 1)
9 men 41.00 ± 16.42
41 (15–66)
3 6 0 7 2 1
Abbreviations: Ab-Ad, abduction-adduction; BoNT, botulinum neurotoxin; F-E, flexion-extension I-E rot, internal-external rotation; IDT, idiopathic, dystonic 
tremor; IT, intention tremor; PD, Parkinson’s disease; P-S, pronosupination; PWT, primary writing tremor.
*Age at onset was unclear in one patient with ET (some time in childhood); **Holmes tremor resulted from focal, cerebral lesions (thalamic, ischemic stroke: n = 5; 
thalamic hematoma: n = 2; thalamic teratoma: n = 1).
All data are quoted as the mean ± standard deviation and the median (range).
Table 2. Botulinum Neurotoxin Injections
Age at first 
injection (years)
Dose of  the first 
injection (Ona 
units per limb)
Number of  cycles Last injection
Age (years) Dose (Ona units  
per limb)















(weakness in all 
cases)
Abbreviations: Abo, abobotulinumtoxin A; BoNT, botulinum neurotoxin; Inco, incobotulinumtoxin A; Ona, onabotulinumtoxin A.
All data are quoted as the mean ± standard deviation and the median (range).
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The doses injected into the target muscles are summarized in 
Supplementary Table 2. The finger muscles were very rarely targeted, 
and the frequencies were similar in the two main indications (ET: 4.6% 
of  the patients; HT: 4.0% of  the patients; this difference was not signif-
icant in Fisher’s exact test). The muscles for hand flexion-extension and 
pronosupination were frequently treated and were more frequently tar-
geted in patients with ET (in 74.4% of  cases) than in patients with HT 
(in 44.2% of  cases; p < 10-5 in a chi-squared test). The most proximal 
muscles (for flexion-extension of  the forearm, and arm movements) 
were more frequently targeted in the HT subgroup (in 42.0% of  cases) 
than in the ET subgroup (in 16.4% of  cases; p < 10-8 in a chi-squared 
test).
Weakness after the last injection was reported by seven patients 
(18.4%); this impairment variously affected the shoulder (n = 1), fore-
arm flexion-extension (n = 1), pronosupination (n = 1), hand flexion-ex-
tension (n = 3), and finger (n = 1).
Discussion
The results of  this study demonstrated an improvement in ADL 
(according to the ETEA) and QoL (according to the QUEST) 1 month 
after BoNT injections in a group of  patients with upper limb tremor. 
Improvements were also observed in ET and HT subgroups. Although 
patients with other types of  tremor experienced an overall improve-
ment, the small sample size prevented us from determining whether this 
difference was statistically significant. These results for ADL and QoL 
corresponded closely to levels of  patient satisfaction; most patients felt 
much or very much improved, according to the CGI-I. In most previous 
studies of  tremor and BoNT treatments, patients were evaluated after a 
single injection; in contrast, our patients had received 12.5 cycles, on 
average. We suspect that repeated injections may be more effective than 
a single injection. Indeed, repeated injections enable the physician to 
adapt the BoNT regimen and the number of  target muscles.
Various drug classes have been used to treat patients with ET, includ-
ing anticonvulsants, beta-adrenergic receptor antagonists, and 
GABAergic agents.26 However, propranolol and primidone – the two 
main oral medications used in this condition – have shown limited func-
tional benefit27 or failed to reduce tremor in 30% of  the patients.26 After 
the failure of  several lines of  oral medication, neurosurgery and BoNT 
injections are ranked equally by today’s guidelines.2,3 Neurosurgery 
mainly targets the ventralis intermedius nucleus (VIM) of  the thalamus, 
Table 3. A Comparison of  the Two Main Subgroups of  Patients
Group Age at disease 
onset (years)
Age at the first BoNT 
injection (years)
Age at the time of  post-
treatment evaluation (years)
Number of  tremor 
modes treated (per 
limb)
BoNT dose (Abo 
units per limb)




















t-value (p) in 
Student’s t-test
1.17 (NS) 5.39 (p < 10-3) 8.24 (p = .01) -1.73 (NS) -2.60 (p = .03)
Abbreviations: Abo, abobotulinumtoxin A; BoNT, botulinum neurotoxin; NS, not significant.
All descriptive data are quoted as the mean ± standard deviation and the median (range).
Table 4. Results for the Patients Interviewed by Phone
Etiology ETEA score at 
baseline
ETEA score after 
BoNT injections
t-value (p) in 
student’s t-Test












































































Abbreviations: BoNT, botulinum neurotoxin; CGI-I, Clinical Global Impression-Improvement; ETEA, Essential Tremor Embarrassment Assessment; 
QUEST, Quality of  Life in Essential Tremor.
All descriptive data are quoted as the mean ± standard deviation and the median (range).
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even though other targets (such as the subthalamic nucleus) have been 
proposed. Several surgical techniques can be used, and these may be 
lesional (focused ultrasound and gamma-knife thalamotomy) or nonle-
sional (high-frequency deep brain stimulation).28,29 The good results 
obtained here and in other studies prompted us to consider the role of  
BoNT treatment in the overall therapeutic strategy. The first question 
relates to the role of  BoNT in ET, with regard to oral medication. 
Prescription of  BoNT injections as a first-line treatment is problematic 
for three main reasons. First, access to this treatment is currently quite 
limited (at least in France) because very few BoNT injectors are suitable 
for treating limb muscles, whereas the prevalence of  ET is elevated.30 
Second, the treatment of  all target muscles in all patients is not realistic. 
Third, there is no evidence to show that BoNT is more effective than 
oral medications. Another question concerns the role of  BoNT with 
regard to lesional neurosurgery and deep brain stimulation. Although 
the latter are highly effective treatments for tremor, we consider that 
BoNT injections should be tried first. In fact, deep brain stimulation is 
associated with a risk of  both short-term (cerebral hemorrhage or infec-
tion) and long-term side effects, and technical problems.31 In one study, 
bilateral thalamotomy was associated with a higher risk of  side effects 
than unilateral thalamotomy.32 Moreover, severe adverse events (such as 
radionecrosis) are possible. Treatment with BoNT has a good short- and 
long-term safety profile,16 and the side effects are always transient.
Oral medications (such as dopaminergic agents, anticholinergics, and 
antiepileptic drugs) are not highly effective for HT. For example, L-dopa 
does not always improve the rest component of  HT.33 Although stereo-
tactic thalamic lesional surgery sometimes gives good results in HT, the 
outcome can also be disappointing.34 Thalamic VIM deep brain stimu-
lation seems to be more efficacious, but there is concern about the 
recurrence of  tremor.35 It has been suggested that dual stimulation has 
been proposed to improve the result.34,35 The zona incerta36 or the glo-
bus pallidus internal nucleus35 can be targeted when the thalamus has 
been damaged. To the best of  our knowledge, BoNT’s efficacy on upper 
limb tremor has never been specifically studied in patients with HT. 
This may be due to the rarity of  this disorder. In addition to being dif-
fuse, HT is often of  high amplitude. Hence, one would not expect 
BoNT to be of  value, especially in terms of  QoL and ADL. In fact, the 
degree of  improvement was very clear and was similar to that observed 
in ET (Table 4). The set of  target muscles differed somewhat, with more 
frequent injections in the shoulder girdle (Table 1). Moreover, the mean 
BoNT dose in the HT subgroup was higher than in the ET subgroup 
(216.13 and 95.43 onabotulinumtoxin A units, respectively).
Even though some encouraging results have been published,12,17–19 
the value of  BoNT injections in Parkinsonian tremor is still subject to 
debate. In view of  the effectiveness of  oral medications and surgery, 
BoNT is rarely indicated in PD patients. Only one patient with PD was 
included in the present study, and the results were satisfactory. In line 
with the literature data, we also observed good outcomes in patients 
with primary writing tremor37 or idiopathic dystonic tremor.16,21 In 
patients with primary writing tremor, the rapid initiation of  BoNT 
injections makes sense because the patients’ response to oral medica-
tions is usually poor. Botulinum neurotoxin is the recommended 
first-line therapy for focal dystonia. However, in the field of  dystonic 
tremor, the value of  BoNT has mainly been demonstrated for the relief  
of  cervical dystonia.38
Even though our study was not designed to determine the best injec-
tion strategy or which patients are the best candidates for BoNT treat-
ment, we feel able to put forward a number of  hypotheses. Although the 
injection regimen differed markedly from one patient to another, some 
muscles were frequently injected (see Supplementary Table 2). The 
muscles for pronosupination and hand flexion-extension were treated in 
more than 90 and 75% of  cases, respectively. The extensors were treated 
somewhat less frequently than the flexors, and received lower doses. 
Proximal (arm and shoulder) muscles were less commonly injected, 
although further studies are needed to determine whether distal tremor 
responds better than proximal tremor. In most of  the literature studies, 
finger muscles were not injected. This might have been due to technical 
difficulties or due to the fear of  inducing motor impairments. If  we now 
focus on the potential “best responders,” the absence of  a correlation 
with the observed improvement in the QUEST, ETEA, or CGI-I scores 
indicates that a positive result can be observed whatever the patient’s 
age or disease duration.
Although the absence of  correlation between tremor severity and age 
or disease duration is somewhat surprising, there are three possible 
explanations. First, the disease did not progress in some patients (e.g., 
stroke patients). Second, the BoNT dose increased between the first and 
last injections. Finally, the small sample size may have biased the result.
With regard to safety, 18.4% of  the patients (with various etiologies) 
reported weakness of  the upper arm 1 month after the injections. In 
view of  the subjective nature of  the evaluation (a phone interview), it is 
not possible to say whether a motor impairment was present. However, 
there are relatively few different types of  side effect after a BoNT injec-
tion. All muscle groups were affected, albeit with different frequencies: 
impaired hand flexion-extension was most common, but the muscles 
responsible for this movement were also those most commonly treated. 
In the literature, the frequency of  this side effect ranges from 15 to 92%, 
and the severity varies.5–8,11,14,15,21 The relatively low percentage of  our 
patients reporting weakness (relative to the literature data) might be 
linked to the progressive adaptation of  the BoNT dose.
The present study had several limitations. First, the retrospective 
design means that our results must be confirmed by a prospective, dou-
ble-blind, placebo-controlled, randomized clinical study. For example, it 
is possible that the open study design favored positive results. Second, 
patients with unsatisfactory results (i.e., those who chose not to continue 
BoNT treatment) were underrepresented in our cohort. However, 
among the 50 patients treated over a 30-month period, only six (12%) 
asked to discontinue BoNT injections due to lack of  efficacy (n = 5) or 
for disabling side effects (n = 1) (Table 3). Third, the small number of  
patients (especially in the HT group and for the other rare forms of  
tremor) constitutes a study limitation. More robust conclusions could be 
obtained by studying a larger sample after, for example, multicenter 
recruitment. It would also have been interesting to determine whether 
the positive impact on QoL and ADL correlated with an objective 
decrease in tremor (with a clinical or a kinematic analysis) and whether 
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the improvement persisted after several months. In the future, a long-
term evaluation (e.g., 8 and 12 weeks after the injections, and over three 
cycles of  injections) would be of  value because repeated injections may 
be more effective than a single injection. Furthermore, it would be of  
value to implement a customized protocol, as already emphasized by 
other groups.8,11,12,14,15,17–19
Further studies are necessary to (1) confirm the efficacy of  BoNT in 
patients with various etiologies of  upper limb tremor and (2) address the 
following questions: Which patients are the best responders? Does the 
treatment response depend on, for example, disease etiology, tremor 
topography, or patient expectations? And do certain muscles (proximal 
vs. distal) and types of  tremor (rest tremor, postural tremor, action 
tremor, etc.) respond better to BoNT?
Acknowledgments
The authors wish to thank Dr David Fraser (Biotech Communication 
SARL, Ploudalmézeau, France) for editorial assistance.
References
1. Louis ED, Machado DG. Tremor-related quality of  life: a comparison 
of  essential tremor vs. Parkinson’s disease patients. Parkinsonism Relat Disord 
2015;21:729–735. doi: 10.1016/j.parkreldis.2015.04.019
2. Zesiewicz TA, Elble RJ, Louis ED, Gronseth GS, Ondo WG, Dewey RB, 
et al. Evidence-based guideline update: treatment of  essential tremor: report of  
the Quality Standards subcommittee of  the American Academy of  Neurology. 
Neurology 2011;77:1752–1755. doi: 10.1212/WNL.0b013e318236f0fd
3. Zappia M, Albanese A, Bruno E, Colosimo C, Filippini G, Martinelli P, 
et al. Treatment of  essential tremor: a systematic review of  evidence and rec-
ommendations from the Italian Movement Disorders Association. J Neurol 
2013;260:714–740. doi: 10.1007/s00415-012-6628-x
4. Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, 
et al. Review of  the  therapeutic management of  Parkinson’s disease. Report 
of  a joint task force of  the European Federation of  Neurological Societies 
(EFNS) and the Movement Disorder Society-European Section (MDS-ES). 
Part II: late (complicated) Parkinson’s disease. Eur J Neurol 2006;13:1186–1202. 
doi: 10.1111/j.1468-1331. 2006.01548.x
5. Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J. A ran-
domized, double-blind, placebo-controlled study to evaluate botulinum toxin 
type A in essential hand tremor. Mov Disord 1996;11:250–256. doi: 10.1002/
mds.870110306
6. Henderson JM, Ghika JA, Van Melle G, Haller E, Einstein R. 
Botulinum toxin A in non-dystonic tremors. Eur Neurol 1996;36:29–35. doi: 
10.1159/000117196
7. Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL, et al. 
A randomized, double masked, controlled trial of  botulinum toxin type A in 
essential hand tremor. Neurology 2001;56:1523–1528. doi:10.1212/wnl.56.11.1523
8. Pacchetti C, Mancini F, Bulgheroni M, Zangaglia R, Cristina S, Sandrini G, 
Nappi G. Botulinum toxin treatment for functional disability induced by essential 
tremor. Neurol Sci 2000;21:349–353. doi:10.1007/s100720070049
9. Bain P, Findley L, editors. Assessing tremor severity: a clinical handbook. London, 
United Kingdom: Smith-Gordon; 1993. ISBN 1-85463-099-7.
10. Koller WC, Busenbark K, Hubble J. Essential tremor. In: Calne DB, 
 editor. Neurodegenerative diseases. Philedelphia, PA: WB Saunders; 1994, 
pp. 717–742. ISBN 0721643493.
11. Samotus O, Rahimi F, Lee J, Jog M. Functional ability improved in essen-
tial tremor by IncobotulinumtoxinA injections using kinematically determined 
biomechanical patterns – A new future. PLoS One 2016;11(4):e0153739. doi: 
10.1371/journal.pone.0153739
12. Samotus O, Lee J,  Jog M. Long-term tremor therapy for Parkinson and 
essential tremor with sensor-guided botulinum toxin type A injections. PLoS One 
2017;12(6):e0178670. doi: 10.1371/journal.pone.0178670
13. Samotus O, Kumar N, Rizek P,  Jog M. Botulinum toxin type A injections 
as monotherapy for upper limb essential tremor using kinematics. Can J Neurol Sci 
2018;45:11–22. doi: 10.1017/cjn.2017.260
14. Jog M, Lee J, Althaus M, Scheschonka A, Dersch H, Simpson D. 
Efficacy and safety of  incobotulinumtoxinA (Inco/A) for essential tremor of  
the upper limb using kinematics-guided clinical decision support: a random-
ized,  double-blind, placebo-controlled trial. Mov Disord 2017;32(Suppl. 2):S451. 
doi:10.1002/mds.27087 
15. Mittal SO, Machado D, Richardson D, Dubey D, Jabbari B. Botulinum 
toxin in essential hand tremor – A randomized double-blind placebo-con-
trolled study with customized injection approach. Parkinsonism Relat Disord 
2018;56:65–69. doi: 10.1016/j.parkreldis.2018.06.019
16. Niemann N, Jankovic J. Botulinum toxin for the treatment of  hand tremor. 
Toxins 2018;10:E299. doi: 10.3390/toxins10070299
17. Rahimi F, Bee C, Debicki D, Roberts AC, Bapat P,  Jog M. Effectiveness of  
BoNT A in Parkinson’s disease upper limb tremor management. Can J Neurol Sci 
2013;40:663–669. doi:10.1017/S031716710001489X
18. Rahimi F, Samotus O, Lee J,  Jog M. Effective management of  upper limb 
Parkinsonian tremor by IncobotulinumtoxinA injections using sensor-based bio-
mechanical patterns. Tremor Hyperkinetic Mov 2015;5:348. doi: 10.7916/D8BP0270
19. Mittal SO, Machado D, Richardson D, Dubey D, Jabbari B. Botulinum 
toxin in Parkinson disease tremor: a randomized, double-blind, placebo-controlled 
study with a customized injection approach. Mayo Clin Proc 2017;92:1359–1367. 
doi: 10.1016/j.mayocp.2017.06.010
20. Vielotte J. Effectiveness of  intramuscular injections of  botulinum toxin in 
the treatment of  disabling cerebellar tremor of  the hand. Ann Phys Rehabil Med 
2016;59(S):e142. doi: 10.1016/j.rehab.2016.07.319
21. Kim SD, Yiannikas C, Mahant N, Vucic S, Fung VSC. Treatment 
of  proximal upper limb tremor with botulinum toxin therapy. Mov Disord 
2014;29:835–838. doi: 10.1002/mds.25739
22. Bhatia KP, Bain P, Bajaj N, Elble RJ, Hallett M, Louis ED, et al. 
Consensus statement on the classification of  tremors, from the task force on 
tremor of  the International Parkinson and Movement Disorder Society. Mov 
Disord 2018;33:75–87. doi: 10.1002/mds.27121
23. Tröster AI, Pahwa R, Fields JA, Tanner CM, Lyons KE. Quality of  
life in Essential Tremor Questionnaire (QUEST): development and ini-
tial  validation. Parkinsonism Relat Disord 2005;11:367–373. doi: 10.1016/j.
parkreldis.2005.05.009
24. Traub RE, Gerbin M, Mullaney MM, Louis ED. Development of  an essen-
tial tremor embarrassment assessment. Parkinsonism Relat Disord 2010;16:661–665. 
doi: 10.1016/j.parkreldis.2010.08.017
Kreisler A, Bouchain B, Defebvre L, et al. BoNT in Upper Limb Tremor
Columbia University Libraries
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org 7
25. Guy W, editor. Clinical global impressions. In: ECDEU assessment man-
ual for psychopharmacology, revised. Rockville, MD: National Institute of  
Mental Health; 1973, pp. 217–221. 
26. Koller WC, Vetere-Overfield B. Acute and chronic effects of  propran-
olol and primidone in essential tremor. Neurology 1989;39:1587–1588. doi.
org/10.1212/WNL.39.12.1587
27. Rajput AH, Rajput A. Medical treatment of  essential tremor. J Cent Nerv 
Syst Dis 2014;6:29–39. doi: 10.4137/JCNSD.S13570
28. Picillo M, Fasano A. Recent advances in essential tremor: surgical treat-
ment. Parkinsonism Relat Disord 2016;22 Suppl 1:S171–S175. doi: 10.1016/j.
parkreldis.2015.09.012
29. Witjas T, Carron R, Krack P, Eusebio A, Vaugoyeau M, Hariz M, et al. 
A prospective single-blind study of  Gamma Knife thalamotomy for tremor. 
Neurology 2015;85:1562–1568. doi: 10.1212/WNL.0000000000002087
30. Louis ED, Ferreira JJ. How common is the most common adult movement 
disorder? Update on the worldwide prevalence of  essential tremor. Mov Disord 
2010;25:534–541. doi: 10.1002/mds.22838
31. Buhmann C, Huckhagel T, Engel K, Gulberti A, Hidding U, Poetter-
Nerger M, et al. Adverse events in deep brain stimulation: a retrospective long-
term analysis of  neurological, psychiatric and other occurrences. PLoS One 
2017;12(7):e0178984. doi: 10.1371/journal.pone.0178984
32. Tasker RR. Deep brain stimulation is preferable to thalamotomy for tremor 
suppression. Surg Neurol 1998;49:145–153. doi:10.1016/S0090-3019(97) 00459-X
33. Raina GB, Cersosimo MG, Folgar SS, Giugni JC, Calandra C, Paviolo JP, 
et al. Holmes tremor: clinical description, lesion localization, and treat-
ment in a series of  29 cases. Neurology 2016;86:931–938. doi: 10.1212/WNL. 
0000000000002440
34. Kobayashi K, Katayama Y, Oshima H, Watanabe M, Sumi K, Obuchi T, 
et al. Multitarget, dual-electrode deep brain stimulation of  the thalamus and 
 subthalamic area for treatment of  Holmes’ tremor. J Neurosurg 201;120:1025–1032. 
doi: 10.3171/2014.1.JNS12392
35. Ramirez-Zamora A, Okun MS. Deep brain stimulation for the treatment 
of  uncommon tremor syndromes. Expert Rev Neurother 2016;16:983–997. doi: 
10.1080/14737175.2016.1194756
36. Plaha P, Khan S, Gill SS. Bilateral stimulation of  the caudal zona incerta 
nucleus for tremor control. J Neurol Neurosurg Psychiatry 2008;79:504–513. doi: 
10.1136/jnnp.2006.112334
37. Hai C, Yu-ping W, Hua W, Ying S. Advances in primary writ-
ing tremor. Parkinsonism Relat Disord 2010;16:561–565. doi: 10.1016/j.
parkreldis.2010.06.013
38. Pandey S, Sarma N. Tremor in dystonia. Parkinsonism Relat Disord 
2016;29:3–9. doi: 10.1016/j.parkreldis.2016.03.024
